ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease ...

Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...

The UAE is rapidly consolidating its position as a global pharmaceutical and life sciences hub, with the national market ...

Science-backed adjustments to your stride could be the ultimate weapon against osteoporosis and age-related muscle decline.

After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

A collaborative team of researchers and students from Wayne State University's Eugene Applebaum College of Pharmacy and ...

These results once again have the potential to deliver a best in class profile with pivotal data expected this year or next ...

Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with ...

Alzheimer's disease is often measured in statistics: millions affected worldwide, cases rising sharply, costs climbing into the trillions. For families, the disease is experienced far more intimately.

DNA is often described as the instruction manual for building the fundamental components of life. Proteins are helpers that ...